PYO/SB/08b (12-08)

Approved for use through 01/31/2009\_OMS 0651-0631 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE.

Substitute for form 1449/PTO	Complete if Known	
INFORMATION DIGGLOOUSE		10/600,361
		June 20, 2003
STATEMENT BY APPLICANT	First Named Inventor	Jean-Marie Andrieu et al.
	Art Unit	1648
<del></del>		Emily M. Le
Sheet 1 of 6	Attorney Docket Number	1187-R-02

NON PATENT LITERATURE DOCUMENTS Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of Initials\* No. the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. ANDRIEU, J.-M. et al., "Viro-immunopathogenesis of HIV Disease: Implications for Therapy," Immunology Today, 1995, vol. 16, no. 1, pages 5-7. BAROUCH, D. H. et al., "Eventual AIDS Vaccine Failure in a Rhesus Monkey by Viral Escape from Cytotoxic T Lymphocytes," Nature, January 17, 2002, vol. 415, pages 335-BÖHLER, T. et al., "T-Cell Apoptosis in HIV-1-Infected Individuals Receiving Highly Active Antiretroviral Therapy," Blood, March 15, 2001, vol. 97, no. 6, pages 1898-1901 CAVERT, W. et al., "Kinetics of Response in Lymphoid Tissues to Antiretroviral Therapy of HIV-1 Infection," Science, May 9, 1997, vol. 276, pages 960-964. CHAMPAGNE, P. et al., "Skewed Maturation of Memory HIV-Specific CD8 T Lymphocytes," Nature, March 1, 2001, vol. 410, pages 106-111. CHOUGNET, C. et al., "Normal Immune Function of Monocyte-Derived Dendritic Cells from HIV-Infected Individuals: Implications for Immunotherapy," The Journal of Immunology, 1999, vol. 163, pages 1666-1673. CHUN, T.-W. et al., "Presence of an Inducible HIV-1 Latent Reservoir during Highly Active Antiretroviral Therapy," Proc. Natl. Acad. Sci. USA, November 1997, vol. 94. pages 13193-13197. COHEN, O. J. et al., "Host Factors in the Pathogenesis of HIV Disease," Immunological Reviews, 1997, vol. 159, pages 31-48. COLLIER, A. C. et al., "Treatment of Human Immunodeficiency Virus Infection with Saquinavir, Zidovudine, and Zaicitabine," The New England Journal of Medicine, April 18, 1996, vol. 334, no. 16, pages 1011-1017. DAVEY, R. T. Jr. et al., "HIV-1 and T Cell Dynamics after Interruption of Highly Active Antiretroviral Therapy (HAART) in Patients with a History of Sustained Viral Suppression," PNAS, December 21, 1999, vol. 96, no. 26, pages 15109-15114.

Examiner Signature	/Emily Le/	Date Considered	10/28/2009
EXAMINER Initi	al if reference considered, whether or not citation i	s in conformance with MPEP 609. Draw line through cit	ation if not in conformance

and not considered, include copy of this form with next communication to applicant,

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

<sup>1</sup> Applicant's unique citation designation number (optional), 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1 14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form anti/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB085 (12-08)
Approved for use through 01/31/2009, OM8 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCED

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO Application Number 10/600.361 INFORMATION DISCLOSURE Filing Date June 20, 2003 STATEMENT BY APPLICANT First Named Inventor Jean-Marie Andrieu et al. Art Linit (Use as many sheets as necessary) Examiner Name Emily M. Le Sheet Attorney Docket Number 1187-R-02

NON PATENT LITERATURE DOCUMENTS Examiner Cite include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of  $T^2$ Initials\* No. the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. DONAGHY, H. et al., "Loss of Blood CD11c" Myeloid and CD11c Plasmacytoid Dendritic Cells in Patients with HIV-1 Infection Correlates with HIV-1 RNA Virus Load." Blood, October 15, 2001, vol. 98, no. 8, pages 2574-2576. FELDMAN, S. et al., "Decreased Interferon-α Production in HIV-Infected Patients. Correlates with Numerical and Functional Deficiencies in Circulating Type 2 Dendritic Cell Precursors," Clinical Immunology, November 2001, vol. 101, no. 2, pages 201-210. FENYÖ, E. M. et al., "Broad Cross-Neutralizing Activity in Serum Is Associated with Slow Progression and Low Risk of Transmission in Primate Lentivirus Infections." immunology Letters, 1996, vol. 51, pages 95-99. FINZI, D. et al., "Latent Infection of CD4" T Cells Provides a Mechanism for Lifelong Persistence of HIV-1, Even in Patients on Effective Combination Therapy," Nature Medicine, May 1999, vol. 5, no. 5, pages 512-517. GRABAR, S. et al., "Clinical Outcome of Patients with HIV-1 Infection According to Immunologic and Virologic Response after 6 Months of Highly Active Antiretroviral Therapy," Annals of Internal Medicine, September 19, 2000, vol. 133, no. 6, pages 401-GRASSI, F. et al., "Depletion in Blood CD11c-Positive Dendritic Cells from HIV-Infected Patients," AIDS, 1999, vol. 13, no. 7, pages 759-766. GRAY, C. M. et al., "Frequency of Class I HLA-Restricted Anti-HIV CD8" T Cells in Individuals Receiving Highly Active Antiretroviral Therapy (HAART)," The Journal of immunology , 1999, vol. 162, pages 1780-1788. HARRIGAN, P. R. et al., "Rate of HIV-1 RNA Rebound upon Stopping Antiretroviral Therapy," AIDS, 1999, vol. 13, no. 8, pages F59-F62. HATANO, H. et al., "Pre-HAART HIV Burden Approximates Post-HAART Viral Levels Following Interruption of Therapy in Patients with Sustained Viral Suppression," AIDS, 2000, vol. 14, no. 10, pages 1357-1363. HAYNES, B. F. et al., "Toward an Understanding of the Correlates of Protective Immunity to HIV Infection," Science, January 19, 1996, vol. 271, pages 324-328.

Examiner	/Carlled al	Date	10/00/0000
Signature	/Emily Le/	Considered	10/26/2009

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 600. Draw line through oitation if not in conformance and not considered, incude copy of this form with next communication to applicant.

Applicant's injury citation designation number (policional): 2 Applicant is not ac a check mark here if English language Translation is attached. This

collection of information is roughled by 37 CFR 1.88. The information is required to obtain or retain a bernetif by the public which is to life (lend by the USFTO of process) an application. Confidentiation is required by 38 U.S. C. 122 and 37 CFR 1.14. This collection is externated to take 2 hours to complete, including gethering proparing, and submitting the completed application form to the USFTO. There will very depending upon the individual cases. Any comments on the amount of time you required to complete this form anders suggestions for reducing this buries, should be sent to the Chief Information Cifficer, U.S. Pattert and Tindowark Office, P.O. Box 1480, Alexandris, V.A. 22315-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patterts, P.O. Box 1490, Alexandris, V.A. 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2

EAST\42522495.1

Sheet

(Use as many sheets as necessary)

of

and not considered. Include copy of this form with next communication to applicant.

6

PTG/SB/085 (12-08) Approved for use through 01/31/2009 OMB 0651-0031

Under the Pagerwork Reduction Aut of 1995, no persons are required to respond to a collection of information unitest contains at order of the Pagerwork Reduction Aut of 1995, no persons are required to respond to a collection of information unitest contains a valid CMS control number.

Substitute for from 1440PTO

INFORMATION DISCLOSURE
Filing Date

June 20, 2003

STATEMENT BY APPLICANT
First Named Inventor

Juan-Marie Andrieu et al.

At this

Attorney Docket Number 1187-R-02

Emily M. Le

Examiner Name

NON PATENT LITERATURE DOCUMENTS Examiner Cite include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of Initials\* No. the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. HERMANS, I. F. et al., "CD8" T Cell-Dependent Elimination of Dendritic Cells In Vivo Limits the Induction of Antitumor Immunity," The Journal of Immunology, 2000, vol. 164. pages 3095-3101. HIRSCH, V. M. et al., "Simian Immunodeficiency Virus Infection of Monkeys as a Model System for the Study of AIDS Pathogenesis, Treatment, and Prevention," Advances in Pharmacology, 2000, vol. 49, pages 437-477. IBAÑEZ, A. et al., "Quantification of Integrated and Total HIV-1 DNA after Long-Term Highly Active Antiretroviral Therapy in HIV-1-Infected Patients," AIDS, 1999, vol. 13, no. 9. pages 1045-1049 JIN, X, et al., "An Antigenic Threshold for Maintaining Human Immunodeficiency Virus Type 1-Specific Cytotoxic T Lymphocytes," Molecular Medicine, 2000, vol. 6, no. 9, pages 803-809. KALAMS, S. A. et al., "Levels of Human Immunodeficiency Virus Type 1-Specific Cytotoxic T-Lymphocyte Effector and Memory Responses Decline after Suppression of Viremia with Highly Active Antiretroviral Therapy," Journal of Virology, August 1999, vol. 73, no. 8, pages 6721-6728 KAUFMANN, D. et al., "CD4-Cell Count in HIV-1-Infected Individuals Remaining Viraemic with Highly Active Antiretroviral Therapy (HAART)," The Lancet, March 7. 1998, vol. 351, pages 723-724. KNIGHT, S. C. et al., "Antigen-Presenting Cell Types," Current Opinion Immunology, 1993, vol. 5, pages 374-382. KOSTENSE, S. et al., "Persistent Numbers of Tetramer+ CD8+ T Cells, but Loss of Interferon-gamma + HIV-Specific T Cells During Progression to AIDS," Blood, April 1, 2002, vol. 99, no. 7, pages 2505-2511 LEDERGERBER, B. et al., "Clinical Progression and Virological Failure on Highly Active Antiretroviral Therapy in HIV-1 Patients: a Prospective Cohort Study," The Lancet, March 13, 1999, vol. 353, pages 863-868. LEDERMAN, M. M. et al., "Immune Restoration with Antiretroviral Therapies: Implications for Clinical Management," JAMA, July 12, 2000, vol. 284, no. 2, pages 223-228.

Examiner Signature	/Emily Le/	Date Considered	10/28/2009	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 600. Draw line through citation if not in conformance				

1 Application's unique ordation designation number (optional), 2 Applicants to place a check mark terril English language Translation is attached. This collection of information is required by 3°C FER 1.88. This discrimination is required by 3°C FER 1.88. This discrimination is required by 3°C FER 1.88. This collection is discrimination in the property of the prop

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

EAST/42522495.1

PTO/SB/085 (12-08)

Approved for use through 01/31/2009. GMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB or

Substitute for form 1449/PTO	Complete if Known		
111505111151151151151151		10/600,361	
		June 20, 2003	
STATEMENT BY APPLICANT	First Named Inventor	Jean-Marie Andrieu et al.	
	Art Unit	1648	
(Use as many sheets as necessary)	Examiner Name	Emily M. Le	
Sheet 4 of 6	Attorney Docket Number	1187-R-02	

NON PATENT LITERATURE DOCUMENTS

Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	-
Initials*	No.2	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue	T <sup>2</sup>
	<del> </del>	number(s), publisher, city and/or country where published.  LEVITZ, S. M., "Improvement in CD4+ Cell Counts Despite Persistently Detectable HIV	
	1	Load," The New England Journal of Medicine, April 9,1998, vol. 338, no. 15, pages	
		1074-1075.	
	1	LU, W. et al., "Prospective Views of HIV Pathology. Clues for Therapeutic Strategies,"	
		Cell Activation Apoptosis in HiV Infection, Plenum Press, NY, 1995, pages 235-242.	
		LU, W. et al., "Enhanced Dendritic Cells-Driven Proliferation and Anti-HIV Activity of	
		CD8* T Cells by a New Phenothiazine Derivative, Aminoperazine," The Journal of Immunology, 2001, vol. 167, pages 2929-2935.	
		LU, W. et al. T-Cell Recovery in HiV-Infected Patients Experiencing Virologic Fallure under Highly Active Antiretroviral Therapy, Blood. 2001b, vol. 97, pages 1900-1901.	
		LU, W. et al., "Multi-Target PCR Analysis by Capillary Electrophoresis and Laser- Induced Fluorescence," Nature, March 17, 1994, vol. 368, pages 269-271.	
	T	LU, W. et al., "Equivalent Amplification of Intrinsically Variable Nucleic Acid Sequences	
		by Multiple-Primer-Induced Overlapping Amplification Assay. Applications for Universal Detection and Quantitation," <u>Nature Medicine</u> , September 1999, vol. 5, no. 9, pages 1081-1085.	
		LUDEWIG, B. et al., "Protective Antiviral Cytotoxic T Cell Memory Is Most Efficiently Maintained by Restinulation via Dendritic Cells," <u>The Journal of Immunology</u> , 1999, vol. 103, pages 1839-1844.	
		Moll.ROY, D. et al., "Low CD83, but Normal MHC Class II and Costimulatory Molecule Expression, on Spleen Dendritic Cells from HIV" Patients," <u>AIDS Research and Human</u> <u>Retroviruses</u> , 1998, vol. 14, no. 6, pages 505-513.	***************************************
		McMiCHAEL, A. J. et al., "Escape of Human Immunodeficiency Virus from Immune Control," Annu. Rev. Immunology, 1997, vol. 15, pages 271-296.	
		MEHLHOP, E. et al., "Enhanced in Vitro Stimulation of Rhesus Macaque Dendritic Cells	
		for Activation of SIV-Specific T Cell Responses," <u>Journal of Immunology Methods</u> , 2002, vol. 260, pages 219-234.	
		NAIR, S. K. et al., "Induction of Primary Carcinoembryonic Antigen (CEA)-Specific Cytotoxic T Lymphocytes in Vitro Using Human Dendritic Cells Transfected with RNA," Nature Biotechnology, April 1998, vol. 16, pages 364-369.	

Examiner Signature	/Emily Le/	Date Considered	10/28/2009

ther or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique oftation designation number (optional), 2 Applicant is to place a check mark here if English language Translation is attached. This

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

FASTM2522495 1

Ordifection of immutes consume interpressors consume (spinuses). a repressor or a press or short or retains a female to the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S. C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gethering, preparing, and submitting the completed application form to the USPTO. Time will vary depending input the individual case. Any comments on the amount of time your require to complete this form and/or suggestions for reducing the first strength in transmission of the amount of time your require to complete this form and/or suggestions for reducing the first, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1459, Alexandria, VA 22313-1459.

PTO/SB/98b (12:08)
Approved for use through 01/31/2009 OMB 0691:0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for Pepervoich Reduction Act of 1995, no persons are required to reaponed to a catecise of elementary unless it sometime a valid Outh control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use at mainy sheets as necessary)

(Use at mainy sheets as necessary)

Sheet 5 of 6 Attorney Docket Number | 1878-02

NON PATENT LITERATURE DOCUMENTS Examiner Cite include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of Initials\* No.1 the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue 72 number(s), publisher, city and/or country where published. NORBURY, C. C. et al., "Visualizing Priming of Virus-Specific CD8" T Cells by Infected Dendritic Cells In Vivo, Nature Immunology, March 2002, vol. 3, no. 2, pages 265-271. PACANOWSKI, J. et al., "Reduced Blood CD123+ (Lymphoid) and CD11c+ (Myeloid) Dendritic Cell Numbers in Primary HIV-1 Infection," Blood, November 15, 2001, vol. 98, no. 10, pages 3016-3021. ROSSIO, J. L. et al., "inactivation of Human Immunodeficiency Virus Type 1 Infectivity with Preservation of Conformational and Functional Integrity of Virion Surface Proteins, Journal of Virology, October 1998, vol. 72, no. 10, pages 7992-8001. SALERNO-GONÇALVES, R. et al., "Quantitative Analysis of the Antiviral Activity of CD8\* T Cells from Human Immunodeficiency Virus-Positive Asymptomatic Patients with Different Rates of CD4\* T-Cell Decrease," Journal of Virology, July 2000, vol. 74, no. 14, pages 6648-6651. SALERNO-GONÇALVES, R. et al., "Lysis of CD4" T Cells Expressing HIV-1 Gag Peptides by Gag-Specific CD8\* Cytotoxic T Cells." Immunology Letters, 1998, vol. 64. SANTINI, S. M. et al., "Type I Interferon as a Powerful Adjuvant for Monocyte-Derived Dendritic Cell Development and Activity In Vitro and in Hu-PBL-SCID Mice," J. Exp. Med., May 15, 2000, vol. 191, no. 10, pages 1777-1788. SAPP, M. et al., "Dendritic Cells Generated from Blood Monocytes of HIV-1 Patients Are. Not Infected and Act as Competent Antigen Presenting Cells Eliciting Potent T-Cell Responses," Immunology Letters, 1999, vol. 66, pages 121-128. SLOAND, E. M., et al., "Human Immunodeficiency Virus Type 1 Protease Inhibitor Modulates Activation of Peripheral Blood CD4+ T Cells and Decreases Their Susceptibility to Apoptosis In Vitro and In Vivo," Blood, August 1, 1999, vol. 94, no. 3. pages 1021-1027. STRAUCHEN, J. et al., "Criteria for the Diagnosis of Acute Megakaryocytic Leukemia." Blood, 2001, vol. 97, pages 1898-1901. WILSON, C. C. et al., "HIV-1-Specific CTL Responses Primed In Vitro by Blood-Derived Dendritic Cells and Th1-Biasing Cytokines," The Journal of Immunology, 1999, vol. 162, pages 3070-3078.

Signature	/Emily Le/	Date Considered	10/28/2009
EXAMINER IN	all it reference considered, whether or not citation is in conformance with MPEP 60	9. Draw line through cit	ation if not in conformance
and not consider	ed include copy of this form with next communication to applicant,		

1 Applicants unique diation designation number (optionals 2 Applicant is to place a check mark here if Emiglish language Translation is attached. This confection of information is required by 37 CPF 1.8.1. The mortisation is required by 37 CPF 1.8.1. The mortisation is required by 38 U.S. C. 122 and 37 CPF 1.1.1. This collection is estimated to take a check the best of the USFTO to proceed any application. Confidentially is governed by 38 U.S. C. 122 and 37 CPF 1.1.1. This collection is estimated to take 2 hours to complete, floridation from the text SETO. This will vary desembling one in individual complete, in the confidential of the Confidential Confidentia

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

EAST)42522495.1

PTO/SB/08b (12-08)
Approved for use through 01/31/2009. OMB 0681-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

	Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid QMB control number.					
				Complete if Known		
			a. aa		10/600,361	
				Filing Date	June 20, 2003	
		First Named Inventor	Jean-Marie Andrieu et al.			
		Art Unit	1648			
	(Use as many she	ets as ne	cessary)	Examiner Name	Emily M. Le	
Sh	et 6	of	6	Attorney Docket Number	1187-R-02	
Sh	(Use as many sheets as necessary) Sheet 6 of 6		Examiner Name	Emily M. Le		

Examiner Initials\*

No.

Include name of the author (in CAPITAL ETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, sympostum, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where publishes.

ZHANG, Z.-Q. et al., "Sexual Transmission and Propagation of SIV and HIV in Resting and Activated CD4\* T Cells." Science, November 12, 1999, vol. 286, pages 1353-1357.

ZIMMER, M. I. et al., "Disrupted homeostasis of Langerhans Cells and Interdigitating Dendritic Cells in Monkeys with AIDS," Blood, April 15, 2002, vol. 99, no. 8, pages 2859-2868.

10ignature	Emily Le/	Date Considered	10/28/2009
"EXAMINER: Initial if re and not considered, inc	eference considered, whather or not citation is in conformance with MPEP 60 blude copy of this form with next communication to applicant.	9 Draw line through cit	ation if not in conformance

1 Acolisatists unique clusters resignation number replaced; 2. Applicates it is place a cheek mark here if English language Translations attached. This collection of information a required by 37 CPE 1.80. This micromaters in exquired to obtain or retain a hearest by the public, which is to file of by the USF1O to process an application. Confidentially is governed by 38 LS C. 122 and 37 CFE 1.14. This collection is estimated to sake 2 hours to complete, including glathering, preparing, and adulthing the completed application from the to USF1O. There will very begreding upon the individual committees the improvements are interested to time you implied to complete application from the USF1O. There will very begreding upon the individual committees the improvements are interested to the USF1O CENTRAL CONTRAL CONTRA

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

EAST\42522495.1